entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 16:26:13 - browse：72611

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Phenylephrine and the overlooked value of the placebo effect

focus

WSS

Recent heat wave in the Mediterranean caused by climate change: Study

Bill would stop addiction treatment from triggering child abuse inquiry

Why Charlie Gard's case is so disturbing to Americans

Stroke deaths set to near 10 million globally by 2050

ACA's risk program benefits Blue Cross Blue Shield insurers

Stroke deaths set to near 10 million globally by 2050

focus

entertainment

hotspot

Jerome Adams on the need for new antivirals for Covid

Judge agrees to delay next hearing in Trump classified documents case

Medical leaders decry Supreme Court decision on affirmative action

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

After affirmative action ruling, medical educators look to 'holistic review'

Biden targets hefty hospital 'facility fees' that often surprise patients

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

When women are denied an abortion, their children fare worse than peers

leisure time

3 questions for the future of Biden's cancer moonshot

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Analysis of telehealth claims data suggest service duplication

FDA rejects Alnylam's heart disease treatment over insufficient data

focus

leisure time

knowledge

hotspot